No Quick End To Brexit Activity Hold At EMA
Executive Summary
As the European Medicines Agency gears up to implement its carefully crafted Brexit business continuity plan, it hopes to be in a position to reintroduce some of its currently suspended/reduced activities in the second half of next year.
You may also be interested in...
Brexit Hits Third Countries – CPPs Delayed
The European Medicines Agency is struggling to meet its 10-day turnaround for issuing certificates of pharmaceutical products (CPPs), documents that many countries outside Europe rely on to make their own regulatory decisions.
Brexit Bites EMA: Huge Staff Losses Freeze Many Projects
The EMA is halting its cherished transparency initiative on study data as it reckons with the fact that many of its employees will not be relocating to its new headquarters in Amsterdam. International collaboration, guidelines development and revision, and the agency's involvement in stakeholder meetings will all be cut back.
UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.